A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. [electronic resource]
Producer: 20131113Description: 2972-8 p. digitalISSN:- 1879-0852
- Administration, Oral
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Capsules
- Carcinoma, Ovarian Epithelial
- Diarrhea -- chemically induced
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Fatigue -- chemically induced
- Female
- Humans
- Middle Aged
- Nausea -- chemically induced
- Neoplasm Recurrence, Local
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Phthalazines -- administration & dosage
- Piperazines -- administration & dosage
- Poly(ADP-ribose) Polymerase Inhibitors
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- metabolism
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Tablets
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.